News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Oxygen Biotherapeutics, Inc. (OXBO) Signs Cooperative Research and Development Agreement With U.S. Navy to Investigate the Use of Oxycyte PFC Emulsion as an Adjunctive Treatment of Complex Infected Wounds and Related Injuries



10/3/2012 10:07:03 AM

MORRISVILLE, N.C.--(BUSINESS WIRE)--Oxygen Biotherapeutics, Inc. (“OBI”) (NASDAQ: OXBT) is pleased to report that the U.S. Navy plans to initiate preclinical studies to investigate the potential use of OBI’s proprietary perfluorocarbon emulsion, Oxycyte®, as an intravenously delivered adjunctive treatment for complex infected wounds and related injuries. This research will be conducted under a Cooperative Research and Development Agreement. The primary purpose of the research is to assess the efficacy of Oxycyte for the treatment of infected and/or ischemic wounds. The study protocols and timeline are under development at this time.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES